Puja Sapra is Vice President at the Oncology Research and Development Group. Dr. Sapra leads the research group responsible for preclinical development of targeted therapeutics including nanomedicines, bioconjugates and antibody drug conjugate. Her group has built novel sophisticated technologies to develop antibody drug conjugate molecules and has advanced several of these candidate molecules to clinical trials. Dr. Sapra received her PhD in Pharmacology from University of Alberta, Canada, her BS from All India Institute of Medical Sciences, and her MS in Pharmacology from UK. She is an author of >50 scientific publications, book chapters and co-inventor on several issued patents.
Biology